The safety of fibrin sealants

Cardiovascular Surgery

Volumn 11, Issue SUPPL. 1, 2003, Pages 23-28

  Joch, Christine ^a  

^a SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

Author keywords

Adverse events; Antifibrinolytic agents; Aprotinin; Biological products; Drug contamination; Fibrin sealants; Isolation and purification; Safety; Standards

Indexed keywords

APROTININ; BLOOD CLOTTING FACTOR 13; FIBRIN GLUE; FIBRINOGEN; THROMBIN;

BIOSAFETY; BLOOD DONOR; BRAIN SPONGIOSIS; CATTLE; HEPATITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; NUCLEIC ACID AMPLIFICATION; PLASMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN PURIFICATION; REVIEW; SCREENING; VIRUS INACTIVATION; VIRUS TRANSMISSION; ZOONOSIS;

EID: 0038038285     PISSN: 09672109     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0967-2109(03)00068-1     Document Type: Article

References (32)

1. Holland P.V. Viral infections and the blood supply. New England Journal of Medicine. 334:1996;1734-1735.
2. Infectious disease testing for blood transfusions. Journal of the American Medical Association. 274:1995;1374-1379.
3. da Silva Cardoso M., Koerner K., Epple S., et al. Safety of blood products derived from plasma pools: the positive impact of anti-HCV screening on the quality of such products. Vox Sanguinis. 71:1996;184-186.
4. Schreiber G.B., Busch M.P., Kleinman S.H., et al. The risk of transfusion-transmitted viral infections. New England Journal of Medicine. 334:1996;1685-1690.
5. Dodds R.Y. Current viral risks of blood and blood products. Annals of Medicine. 32:2000;469-474.
6. Joch, C., Witzke, G., Gröner, A., et al. Clinical safety of fibrin sealants. In IXth World Congress of Cardio-Thoracic Surgeons, Lisbon, Portugal, 14-17 November 1999.
7. Foster P.R. Prions and blood products. Annals of Medicine. 32:2000;501-513.
8. Committee for Proprietary Medicinal Products (CPMP). Note for guidance on minimising the risk of transmitting animal spongiform encephalopathy agents via medicinal products. CPMP/BWP/1230/98. © EMEA 1999.
9. Tock B., Drohan W., Hess J., et al. Haemophilia and advanced fibrin sealant technologies. Haemophilia. 4:1998;449-455.
10. Jackson M.R., MacPhee M.J., Drohan W.N., et al. Fibrin sealant: current and potential clinical applications. Blood Coagulation and Fibrinolysis. 7:1996;737-746.
11. Christie R.J., Carrington L., Alving B. Postoperative bleeding induced by topical bovin thrombin: report of two cases. Surgery. 121:1997;708-710.
12. Berguer R., Staerkel R., Moore E., et al. Warning: fatal reaction to the use of fibrin glue in deep hepatic wounds. Case reports. Journal of Trauma. 31:1991;408-411.
13. Banninger H., Hardegger T., Tobler A., et al. Fibrin glue in surgery: frequent development of inhibitors of bovine thrombin and human factor V. British Journal of Haematology. 85:1993;528-532.
14. Alving B.M., Weinstein M.J., Finlayson J.S., et al. Further information on the fibrin sealant conference. Reply to Dr Levitsky. Transfusion. 36:1996;845-846.
15. Radosevich M., Goubran H.A., Burnouf T. Fibrin sealant: scientific rationale, production methods, properties, and current clinical use. Vox Sanguinis. 72:1997;133-143.
16. Darling, A.J. Considerations in performing virus spiking experiments and process validation studies. In Virological Safety Aspects of Plasma Derivatives. Developments in Biological Standards. Vol. 81, Brown, F. editor. Basel: Karger, 1993, p 221-229.
17. Horowitz B., Prince A.M., Horowitz M.S., et al. Viral safety of solvent-detergent treated blood products. Brown F. Virological Safety Aspects of Plasma Derivatives. Developments in Biological Standards. 81:1993;147-161 Karger, Basel.
18. Greenhalgh D.G., Gamelli R.L., Lee M., et al. Multicenter trial to evaluate the safety and potential efficacy of pooled human fibrin sealant for the treatment of burn wounds. Journal of Trauma. 46:1999;433-440.
19. Johnson Z., Thornton L., Tobin A., et al. An outbreak of hepatitis A among Irish haemophiliacs. International Journal of Epidemiology. 24:1995;821-828.
20. Kedda M.A., Kew M.C., Cohn R.J., et al. An outbreak of hepatitis A among South African patients with hemophilia: evidence implicating contaminated factor VIII concentrate as source. Hepatology. 22:1995;1363-1367.
21. Hino M., Ishiko O., Honda K.I., et al. Transmission of symptomatic parvovirus B19 infection by fibrin sealant use during surgery. British Journal of Haematology. 108:2000;194-195.
22. Santagostino E., Mannucci P.M., Gringeri A., et al. Transmission of parvovirus B19 by coagulation factor concentrates exposed to 100 degrees heat after lyophilization. Transfusion. 77:1997;517-522.
23. Smith M.P., Rice K.M., Savidge G.F. Successful clinical use of plasma-derived, dual virus inactivated factor VII concentrate incorporating solvent-detergent and dry heat treatment. Thrombosis and Haemostasis. 77:1997;406-407.
24. Dichtelmüller H., Rudnick D., Breuer B., et al. Improvement of virus safety of an S/D-treated factor VIII concentrate by additional dry heat treatment at 100 degrees C. Biologicals. 24:1996;125-130.
25. Alving B.M., Weinstein M.J., Finlayson J.S., et al. Fibrin sealant: summary of a conference on characteristics and clinical uses. Transfusion. 35:1995;783-790.
26. Martinowitz U., Spotnitz W.D. Fibrin tissue adhesives. Thrombosis and Haemostasis. 78:1997;661-666.
27. Erhardt A., Schaefer S., Athanassiou N., et al. Quantitative assay of PCR-amplified hepatitis B virus DNA using a peroxidase-labelled DNA probe and enhanced chemiluminescence. Journal of Clinical Microbiology. 34:1996;1885-1891.
28. Hilfenhaus J., Gröner A., Nowak T., et al. Analysis of human plasma products: polymerase chain reaction does not discriminate between live and inactivated viruses. Transfusion. 37:1997;935-940.
29. Committee for Proprietary Medicinal Products (CPMP). Note for guidance on plasma derived medicinal products (revised). CPMP/BWP/269/95, rev2. © EMEA 1998.
30. Paul Ehrlich Institute. Bekanntmachung über Maßnahmen zur Abwehr von Arzneimittelrisiken: Verminderung des Risikos der Übertragung von Viren durch Arzneimittel, die durch Fraktionierung aus plasma humanen Ursprungs hergestellt werden. 1995.
31. Baxter Healthcare Corporation. Two-component fibrin sealant, vapor heated, Tisseel VH kit. Prescribing information. April 1998.
32. Hilfenhaus J., Weidmann E. Fibrin glue safety: inactivation of potential viral contaminants by pasteurization of the human plasma components. Drug Research. 35:1985;1617-1619.